Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Feb 23 (Reuters) - Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of ...

More sensitive HIT cell therapy shows promise against solid cancers

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...

New strategy grabs cancer's 'undruggable' proteins and throws them in the cellular trash

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don't fight them—throw them in the cellular trash. In a new study published in ...
Science Daily

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By ...

Elicera Therapeutics AB: Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial ...

Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, tod ...

Researchers repurpose existing lung cancer drug to fight ovarian tumors

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Evidence links polyploidy and senescence in bladder cells, with implications for cancer

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...